BACKGROUND: A comprehensive legal framework needs to be developed to run the health services and to regulate the information systems required to manage and to ensure the quality of cancer screening programmes. The aim of our study was to document and to compare the status of legal basis for cervical screening registration in European countries. METHODS: An electronic questionnaire including questions on governance, decision-making structures and legal framework was developed. The primary responses were collected by September 2016. RESULTS: We sent the questionnaire to representatives of 35 European countries (28 countries of the EU, with the United Kingdom included as 4 countries; 4 EFTA member countries: Iceland, Liechtenstein, Norway, and Switzerland); responses were collected from 33 countries. The legal framework makes it possible to personally invite individuals in 29 countries (88%). Systematic screening registration in an electronic registry is legally enshrined in 23 countries (70%). Individual linkage of records between screening and cancer registries is allowed in 19 of those countries. Linkage studies involving cancer and screening registries have been conducted in 15 countries. CONCLUSION: Although the majority of EU/EFTA countries have implemented population-based screening, only half of them have successfully performed record linkage studies, which are nevertheless a key recommendation for quality assurance of the entire screening process. The European legislation is open to the possibility of using health data for these purposes; however, member states themselves must recognize the public interest to create a legal basis, which would enable all the necessary functions for high-quality cancer screening programmes.
- MeSH
- Early Detection of Cancer methods standards MeSH
- Confidentiality legislation & jurisprudence MeSH
- Humans MeSH
- Uterine Cervical Neoplasms diagnosis MeSH
- Registries standards MeSH
- Policy Making MeSH
- Check Tag
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Europe MeSH
BACKGROUND: The HPV prevalence and genotype distribution are important for the estimation of the impact of HPV-based cervical cancer screening and HPV vaccination on the incidence of diseases etiologically linked to HPVs. The HPV genotype distribution varies across different geographical regions. Therefore, we investigated the type-specific HPV prevalence in Czech women and men with anogenital diseases. METHODS: We analyzed 157 squamous cell carcinoma samples, 695 precancerous lesion samples and 64 cervical, vulvar and anal condylomata acuminate samples. HPV detection and typing were performed by PCR with GP5+/6+ primers, reverse line blot assay and sequencing. RESULTS: Thirty different HPV genotypes were detected in our study, HPV 16 being the most prevalent type both in precancerous lesions (45%) and squamous cell carcinomas (59%). In benign lesions, HPV 6 (72%) was the most common type. Altogether, 61% of carcinoma samples and 43% of precancerous lesion samples contained HPV 16 and/or 18. The presence of HPV types related to the vaccinal ones (HPV 31, 45, 33, 52, 58) were detected in 16% of carcinoma samples and 18% of precancerous lesion samples. HPV 16 and/or 18 were present in 76% of cervical cancer samples, 33% of CIN1, 43% CIN2 and 71% of CIN3 samples. HPV types 6 and/or 11 were detected in 84% samples of condylomata acuminate samples. CONCLUSIONS: The prevalence of vaccinal and related HPV types in patients with HPV-associated diseases in the Czech Republic is very high. We may assume that the implementation of routine vaccination against HPV would greatly reduce the burden of HPV-associated diseases in the Czech Republic.
- MeSH
- Adult MeSH
- Uterine Cervical Dysplasia epidemiology virology MeSH
- Genotype MeSH
- Papillomavirus Infections epidemiology virology MeSH
- Condylomata Acuminata epidemiology virology MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Anus Neoplasms epidemiology virology MeSH
- Vulvar Neoplasms epidemiology virology MeSH
- Papillomaviridae genetics MeSH
- Precancerous Conditions epidemiology virology MeSH
- Prevalence MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Carcinoma, Squamous Cell epidemiology virology MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Czech Republic MeSH
- MeSH
- Cytological Techniques trends utilization MeSH
- Molecular Diagnostic Techniques utilization MeSH
- Uterine Cervical Dysplasia diagnosis MeSH
- Financing, Organized MeSH
- Papillomavirus Infections diagnosis MeSH
- Humans MeSH
- Evidence-Based Medicine trends MeSH
- Meta-Analysis as Topic MeSH
- Uterine Cervical Neoplasms diagnosis epidemiology MeSH
- Mass Screening methods utilization MeSH
- Sensitivity and Specificity MeSH
- Check Tag
- Humans MeSH
- Publication type
- Congress MeSH
National and international experts in cervical cancer prevention met at the International Workshop on Human Papillomaviruses and Consensus Recommendations for Cervical Cancer Prevention to review the current evidence and assess the potential for improvement in cervical cancer prevention and to develop plans for implementation of cervical cancer prevention programmes in Croatia. Key recommendations were developed and adopted during the course of the meeting. The process of bringing national experts together with internationally recognized experts in an open forum for the development of consensus recommendations could serve as a model for other countries seeking to implement or improve cervical cancer prevention programmes.
- MeSH
- Uterine Cervical Dysplasia diagnosis prevention & control diagnosis prevention & control MeSH
- European Union MeSH
- Uterine Cervical Neoplasms diagnosis prevention & control MeSH
- Mass Screening methods organization & administration utilization MeSH
- Practice Guidelines as Topic MeSH
- Papillomavirus Vaccines administration & dosage therapeutic use MeSH
- Geographicals
- Croatia MeSH
